Revenue
2022
2023
2024
2025
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $675,000 | $951,000 | — | — |
| Research & development | $9.1M | $20.0M | $12.9M | $12.4M | $6.1M | $1.0M |
| Operating expenses | $29.5M | $32.1M | $21.4M | $19.0M | $9.0M | $2.0M |
| Operating income | −$29.5M | −$32.1M | −$20.8M | −$18.1M | −$9.0M | −$2.0M |
| Operating margin | — | — | −3,077.63% | −1,898.21% | — | — |
| EBITDA | −$29.5M | −$32.1M | −$20.8M | −$17.6M | −$8.5M | −$2.0M |
| EBITDA margin | — | — | −3,076.30% | −1,853.21% | — | — |
| Net income | −$26.6M | −$36.7M | −$30.5M | −$18.1M | −$10.0M | −$2.3M |
| Net profit margin | — | — | −4,525.04% | −1,898.84% | — | — |
| Basic EPSper basic share | -$1.67 | -$5.65 | -$12.80 | -$12.00 | -$8.60 | -$2.70 |
| Diluted EPSper diluted share | -$1.67 | -$5.65 | -$12.80 | -$12.00 | -$8.60 | — |
Reported shareholders
| Holder | % owned |
|---|---|
Nantahala Capital Management, LLC | 10.06%2.8M shares |
Aggarwal Gaurav | ≈6.43%1.79M shares |
BlackRock, Inc. | 5.07%1.41M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.85%1.07M shares |
Octagon Capital Advisors LP | 3.59%1M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.02%564.02K shares |
Vivo Capital, LLC | 1.97%550K shares |
MARSHALL WACE, LLP | 1.97%547.86K shares |
Logos Global Management LP | 1.70%473.56K shares |
STATE STREET CORP | 1.62%450.16K shares |
Diametric Capital, LP | 1.34%374.13K shares |
J. Goldman & Co LP | 1.18%327.35K shares |
DIADEMA PARTNERS LP | 1.09%303.68K shares |
MILLENNIUM MANAGEMENT LLC | 0.97%271.46K shares |
Dauntless Investment Group, LLC | 0.77%214K shares |
CITIGROUP INC | 0.66%182.65K shares |
NORTHERN TRUST CORP | 0.65%181.93K shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 0.61%169.2K shares |
SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.57%160.04K shares |
Jump Financial, LLC | 0.55%153K shares |
Percentages use 27.86M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Unicycive ($UNCY) resubmitted its US application for oxylanthanum carbonate, an investigational oral phosphate binder for dialysis patients with chronic kidney disease. The package includes manufacturing and quality data from a new third-pa ...